Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase [0.03%]
异基因造血干细胞移植受者中的新型冠状病肺炎：移植物嵌合早期的危及生命特征
Chiara Oltolini,Anna Guidetti,Marco Ripa et al.
Chiara Oltolini et al.
Ali T Taher,Achille Iolascon,Charbel F Matar et al.
Ali T Taher et al.
Rare inherited anemias are a subset of anemias caused by a genetic defect along one of the several stages of erythropoiesis or in different cellular components that affect red blood cell integrity, and thus its lifespan. Due to their low pr...
The Perception of Shared Decision-Making in Hematology by Patients and Physicians Seems Satisfactory, but Important Steps are Still Ahead of Us [0.03%]
在血液学中，患者和医师对共同决策感知令人满意，但仍有许多重要的步骤需要完成
Paulus A F Geerts,Trudy van der Weijden,Albine Moser et al.
Paulus A F Geerts et al.
Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial [0.03%]
卡非佐米联合沙利度胺和低剂量地塞米松诱导及巩固治疗新诊断的多发性骨髓瘤移植适应症患者：8个vs 4个诱导周期；Carthadex试验
Ruth Wester,Sonja Zweegman,Bronno van der Holt et al.
Ruth Wester et al.
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report [0.03%]
从高剂量的依库珠单抗转换为拉夫利珠单抗治疗阵发性睡眠性血红蛋白尿：病例报告
Wolfgang Füreder,Peter Valent
Wolfgang Füreder
Case Reports
HemaSphere. 2020 Aug 4;4(4):e455. DOI:10.1097/HS9.0000000000000455 2020
Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic [0.03%]
《COVID-19大流行期间Waldenström巨球蛋白血症患者管理的共识声明》
Dipti Talaulikar,Ranjana H Advani,Andrew R Branagan et al.
Dipti Talaulikar et al.
In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (...
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic [0.03%]
SARS-CoV-2大流行期间如何管理慢性淋巴细胞白血病患者
Davide Rossi,Mazyar Shadman,Adalgisa Condoluci et al.
Davide Rossi et al.
Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and backg...
David G Kent
David G Kent
EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper [0.03%]
欧洲范围内的高质量、经济型精准诊断的获取：EH A立场文件
Elizabeth Macintyre,John Gribben,Konstanze Döhner
Elizabeth Macintyre
Theodora Psaltopoulou,Theodoros N Sergentanis,Vasiliki Pappa et al.
Theodora Psaltopoulou et al.
Various agents are currently under evaluation as potential treatments in the fight against coronavirus disease 2019 (COVID-19). Plasma from patients that have overcome COVID-19 infection, referred to as convalescent plasma, is a treatment o...